Advanced Stage Hepatocellular Carcinoma with Multiple Metastasis and Vascular Thrombosis: A Case of Complete Response to Sorafenib

Authors

  • Adélia Simão Serviço de Medicina Interna A. Centro Hospitalar e Universitário de Coimbra. Coimbra. Departamento de Medicina. Faculdade de Medicina. Universidade de Coimbra. Coimbra.
  • Raquel Silva Serviço de Medicina Interna A. Centro Hospitalar e Universitário de Coimbra. Coimbra. Departamento de Medicina. Faculdade de Medicina. Universidade de Coimbra. Coimbra.
  • Lurdes Correia Serviço de Medicina Interna A. Centro Hospitalar e Universitário de Coimbra. Coimbra. Departamento de Medicina. Faculdade de Medicina. Universidade de Coimbra. Coimbra.
  • Filipe Caseiro Alves Departamento de Radiologia. Centro Hospitalar e Universitário de Coimbra. Coimbra. Departamento de Radiologia. Faculdade de Medicina. Universidade de Coimbra. Coimbra.
  • Armando Carvalho Serviço de Medicina Interna A. Centro Hospitalar e Universitário de Coimbra. Coimbra. Departamento de Medicina. Faculdade de Medicina. Universidade de Coimbra. Coimbra.
  • J. M. Nascimento Costa Serviço de Medicina Interna A. Centro Hospitalar e Universitário de Coimbra. Coimbra. Departamento de Medicina. Faculdade de Medicina. Universidade de Coimbra. Coimbra.

DOI:

https://doi.org/10.20344/amp.6799

Keywords:

Carcinoma, Hepatocellular/drug therapy, Neoplasm Metastasis, Remission Induction, Sorafenib.

Abstract

Sorafenib is a multi-targeted tyrosine kinase inhibitor, with antiangiogenic and antiproliferative properties, approved for the treatment of advanced hepatocellular carcinoma. It induces a significant increase in the median overall survival, despite a complete response to treatment being rare. We report a clinical case of a 60-year-old male with hepatic cirrhosis, Child-Pugh class A and performance status 0, and advanced hepatocellular carcinoma. The primary tumor measured 17 x 8 cm and had diffuse intrahepatic metastization, extensive lung and left adrenal invasion, as well as thrombosis of inferior vena cava, with projection to the right atrium. This patient showed a rapid and complete response to sorafenib, evaluated by mRECIST (modified Response Evaluation Criteria in Solid Tumors), that remains after three years of treatment.

Downloads

AMP29(2)

Downloads

Published

2016-02-29

How to Cite

1.
Simão A, Silva R, Correia L, Alves FC, Carvalho A, Costa JMN. Advanced Stage Hepatocellular Carcinoma with Multiple Metastasis and Vascular Thrombosis: A Case of Complete Response to Sorafenib. Acta Med Port [Internet]. 2016 Feb. 29 [cited 2025 Apr. 9];29(2):139-42. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/6799

Issue

Vol. 29 No. 2 (2016): February

Section

Case Report

License

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.

Crossref
Scopus
Google Scholar
Europe PMC